Hakan Edstrom of Santa Clarita was appointed as MannKind’s CEO by the biomedical company’s board of directors.
Formerly the president, Edstrom stepped up as CEO upon the retirement of the company’s founder, biomedical pioneer Alfred Mann.
This past summer the company received FDA approval for its diabetes treatment, and secured a multi-million dollar licensing agreement with Paris-based Sanofi.
